abs311.txt	background		with	total	and	out-of-pocket	spending	for	oral	oncolytics	rising	there	is	increased	interest	in	choosing	oncology	treatments	based	on	theirclinical	value	relative	to	cost	objective		to	determine	if	out-of-pocket	spending	varied	for	higher	versus	lowerbenefit	oral	oncology	drugs	reimbursed	by	commercial	insurers	methods		this	study	was	a	retrospective	analysis	of	commercial	insurerprescription	drug	claims	filed	between	2007	and	2014	for	13	oral	oncolyticsapproved	before	2009		we	calculated	mean	monthly	out-of-pocket	payment	for	eachfill	by	patient		we	then	categorized	oral	oncolytics	by	their	overall	andprogression-free	survival	benefits	for	each	fda-approved	indication		usingevidence	from	published	studies		we	assessed	the	relationship	of	survival	benefitwith	mean	monthly	out-of-pocket	payment		adjusting	for	demographic	and	plancharacteristics	results		our	population	included	44	113	patients	aged	18-65	years	(mean	52	5	[sd9	4])	with	a	cancer	diagnosis	who	filled	731	354	prescriptions		the	most	commonlyrepresented	oncolytics	were	imatinib	(37	4%	of	fills)		lenalidomide	(17	7%	offills)		and	dasatinib	(10	0%	of	fills)		approximately	32	3%	of	fills	were	fordrug-indication	pairs	with	an	overall	survival	benefit	of	4+	years		in	adjustedanalyses		there	was	no	clear	pattern	to	suggest	that	out-of-pocket	paymentsdiffered	with	drug	indication-specific	survival	benefits		drugs	for	indicationsproviding	>	0	to	1	year	of	overall	survival	benefit	were	significantly	morelikely	to	have	a	lower	out-of-pocket	payment	versus	those	prescribed	off-label	but	there	were	no	significant	differences	in	out-of-pocket	payments	between	drugsand	associated	indications	in	any	other	survival	category	versus	drugs	usedoff-label	conclusions		out-of-pocket	payments	for	oral	oncolytics	were	not	clearly	relatedto	indication-specific	value	in	commercially	insured	patients		this	findingsuggests	that	despite	increased	attention	to	value-	and	indication-based	drugpricing		cost	sharing	for	oral	oncolytics	does	not	currently	reflect	these	goals	disclosures		this	project	was	supported	by	research	scholar	grantrsgi-14-030-01-cphps	from	the	american	cancer	society		the	nih	buildinginterdisciplinary	research	careers	in	women's	health	(bircwh)	k12	program		thenorth	carolina	translational	and	clinical	sciences	institute	(ul1tr001111)	grant	and	k24ca181510	from	the	national	cancer	institute		the	authors	have	nodisclosures		data	from	this	study	were	presented	at	the	2017	american	society	forclinical	oncology	annual	meeting	on	june	5		2017		in	chicago		illinois	
